MTNB Stock, Matinas Biopharma Holdings Inc. Information

Matinas BioPharma is a clinical stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life threatening infections. The Company s proprietary, disruptive technology utilizes lipid crystal nano particle cochleates to nano encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company s lead drug candidate is MAT , an orally administered, encochleated formulation of amphotericin B a broad spectrum fungicidal agent . The Company has an open Investigational New Drug IND application for MAT , which is an orally administered, encochleated formulation of amikacin a broad spectrum aminoglycoside antibiotic agent for acute bacterial infections, including non tuberculous mycobacterium NTM and multi drug resistant gram negative bacterial infections. For more information, please visit www.matinasbiopharma.com lt / td gt